|
Introduction to ERA
ERA Consulting was founded as a result of a management buy-out of
a regulatory function within a toxicology contract research organisation,
to attain independence. As a result, our company can boast a cumulative
history of experience spanning over 20 years, since the early days
of the regulation of products derived from biotechnology in the late
1980s.
Our parent company was founded in Germany in 1993, and a subsidiary
in London followed shortly thereafter in 1995 in response to the establishment
of the European Medicines Agency (EMEA). In response to requests from
our growing US client base, operations were established in the USA
in 1997, with an office in Washington DC. In addition, in the autumn
of 2004 we launched a new office in Brisbane, Australia. Details of
our locations can be found on the Office
Locator page of this website.
During the evolution of our activities during the past 20 years, we
have striven continuously to upgrade and update our scientific expertise,
reaching a balance in the team between long years of experience and
the infusion of know-how in cutting edge technologies. We remain dedicated
to the concept of specialising in biopharmaceutical products, in which
we have the necessary experience and an unparalleled track record
of success. Our team has grown over these years to incorporate new
talent, not only in the scientific field, but also in business development
and client services - Team page.
Not only do we have the necessary scientific expertise, but also the
facilities and equipment for a professional approach to project work.
We have invested both in hardware and software, a keystone to our
philosophy, in order to provide the resources that the discerning
client requires, a factor that differentiates us from others in the
field. Indeed, few, if any other consulting groups of our size can
provide, as we do fully equipped conference rooms and the logistic
advantage of locations in Germany, London (close to the EMEA) Washington,
DC, and Brisbane for agency interactions.
We cordially invite
you to contact us for more information on our consulting organisation. Needless
to say, we would be delighted to have the opportunity
to present ourselves in more detail in a personal meeting.
Last, but not least, we would like to express our thanks to our clients
and business associates for their support and constructive collaborations
during the past 20 years. We are pleased to be able to add value and
provide our services to such a large number of companies throughout
the world, ranging from the large transnational pharmaceutical companies,
to smaller biotech start-ups. ERA has the experience and flexibility
to provide individual solutions for all strategic regulatory affairs
requirements in our industry.
Sincerely,
Christopher Holloway |
|